These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20837825)

  • 1. Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1.
    Heatwole CR; Eichinger KJ; Friedman DI; Hilbert JE; Jackson CE; Logigian EL; Martens WB; McDermott MP; Pandya SK; Quinn C; Smirnow AM; Thornton CA; Moxley RT
    Arch Neurol; 2011 Jan; 68(1):37-44. PubMed ID: 20837825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous longitudinal infusion of rhIGF-1/rhIGFBP-3 in extremely preterm infants: Evaluation of feasibility in a phase II study.
    Hansen-Pupp I; Hellström A; Hamdani M; Tocoian A; Kreher NC; Ley D; Hallberg B
    Growth Horm IGF Res; 2017 Oct; 36():44-51. PubMed ID: 28934640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
    Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes.
    Clemmons DR; Sleevi M; Allan G; Sommer A
    J Clin Endocrinol Metab; 2007 Jul; 92(7):2652-8. PubMed ID: 17426090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical markers of insulin-like growth factor-I misuse in athletes: the response of serum IGF-I, procollagen type III amino-terminal propeptide, and the GH-2000 score to the administration of rhIGF-I/rhIGF binding protein-3 complex.
    Guha N; Erotokritou-Mulligan I; Bartlett C; Nevitt SP; Francis M; Bassett EE; Cowan DA; Sönksen PH; Holt RI
    J Clin Endocrinol Metab; 2014 Jun; 99(6):2259-68. PubMed ID: 24606087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety aspects of longitudinal administration of IGF-I/IGFBP-3 complex in neonatal mice.
    Hellgren G; Han W; Wang X; Löfqvist C; Hagberg H; Mallard C; Hellström A
    Growth Horm IGF Res; 2011 Aug; 21(4):205-11. PubMed ID: 21696987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical markers of recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
    Guha N; Erotokritou-Mulligan I; Nevitt SP; Francis M; Bartlett C; Cowan DA; Bassett EE; Sönksen PH; Holt RI
    Drug Test Anal; 2013; 5(11-12):843-9. PubMed ID: 24173773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose.
    Clemmons DR; Moses AC; Sommer A; Jacobson W; Rogol AD; Sleevi MR; Allan G
    Growth Horm IGF Res; 2005 Aug; 15(4):265-74. PubMed ID: 16005252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effects of Recombinant Human Insulin-Like Growth Factor-I/Insulin-Like Growth Factor Binding Protein-3 Administration on Body Composition and Physical Fitness in Recreational Athletes.
    Guha N; Nevitt SP; Francis M; Woodland JA; Böhning D; Sönksen PH; Holt RI
    J Clin Endocrinol Metab; 2015 Aug; 100(8):3126-31. PubMed ID: 26046967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy--a clinical research center study.
    Vlachopapadopoulou E; Zachwieja JJ; Gertner JM; Manzione D; Bier DM; Matthews DE; Slonim AE
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3715-23. PubMed ID: 8530624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with recombinant human insulin-like growth factor (rhIGF)-I/rhIGF binding protein-3 complex improves metabolic control in subjects with severe insulin resistance.
    Regan FM; Williams RM; McDonald A; Umpleby AM; Acerini CL; O'Rahilly S; Hovorka R; Semple RK; Dunger DB
    J Clin Endocrinol Metab; 2010 May; 95(5):2113-22. PubMed ID: 20233784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel markers to detect recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes.
    Holt RI; Guha N; Böhning W; Bartlett C; Cowan DA; Sönksen PH; Böhning D
    Drug Test Anal; 2017 Jan; 9(1):30-37. PubMed ID: 26888146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated levels of IL-6 and IGFBP-1 predict low serum IGF-1 levels during continuous infusion of rhIGF-1/rhIGFBP-3 in extremely preterm infants.
    Klevebro S; Hellgren G; Hansen-Pupp I; Wackernagel D; Hallberg B; Borg J; Pivodic A; Smith L; Ley D; Hellström A
    Growth Horm IGF Res; 2020 Feb; 50():1-8. PubMed ID: 31756675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of recombinant human insulin-like growth factor-1/insulin-like growth factor binding protein-3 administration on lipid and carbohydrate metabolism in recreational athletes.
    Guha N; Nevitt SP; Francis M; Böhning W; Böhning D; Sönksen PH; Holt RIG
    Clin Endocrinol (Oxf); 2021 Apr; 94(4):551-562. PubMed ID: 33249593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human insulin-like growth factor (IGF)-binding protein-1 inhibits somatic growth stimulated by IGF-I and growth hormone in hypophysectomized rats.
    Cox GN; McDermott MJ; Merkel E; Stroh CA; Ko SC; Squires CH; Gleason TM; Russell D
    Endocrinology; 1994 Nov; 135(5):1913-20. PubMed ID: 7525258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-like growth factor-I treatment in primary growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex.
    Tonella P; Flück CE; Mullis PE
    Horm Res Paediatr; 2010; 73(2):140-7. PubMed ID: 20190552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. rhIGF-1/rhIGFBP-3 in Preterm Infants: A Phase 2 Randomized Controlled Trial.
    Ley D; Hallberg B; Hansen-Pupp I; Dani C; Ramenghi LA; Marlow N; Beardsall K; Bhatti F; Dunger D; Higginson JD; Mahaveer A; Mezu-Ndubuisi OJ; Reynolds P; Giannantonio C; van Weissenbruch M; Barton N; Tocoian A; Hamdani M; Jochim E; Mangili A; Chung JK; Turner MA; Smith LEH; Hellström A;
    J Pediatr; 2019 Mar; 206():56-65.e8. PubMed ID: 30471715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes.
    Saukkonen T; Shojaee-Moradie F; Williams RM; Amin R; Yuen KC; Watts A; Acerini CL; Umpleby AM; Dunger DB
    Diabetes; 2006 Aug; 55(8):2365-70. PubMed ID: 16873702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-administration of insulin-like growth factor (IGF)-I and IGF-binding protein-1 stimulates wound healing in animal models.
    Tsuboi R; Shi CM; Sato C; Cox GN; Ogawa H
    J Invest Dermatol; 1995 Feb; 104(2):199-203. PubMed ID: 7530269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.